Meta and YouTube told a Los Angeles judge that a groundbreaking $6 million verdict against them this year should be reversed.
Investor's Business Daily on MSN
Why Apogee slipped on its Dupixent-rivaling eczema results
Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.
On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) ...
Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce ...
For the second consecutive month, Dupixent finished as the leader among the top 10 Rx and over-the-counter brands. The eczema and asthma drug from Sanofi and Regeneron had an impressions share of ...
Regeneron's EYLEA HD US sales surged 52% in Q1 2026, offsetting competitive pressures and patient switching within the EYLEA ...
TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with ...
Dupixent is a blockbuster immunology drug that just keeps delivering for Sanofi and Regeneron, so it’s no surprise that the “franchise in a therapy” has got a new set of ads. Sanofi and Regeneron, ...
Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2026 adjusted earnings per share (EPS) of $9.47, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results